Humana Inc. (NYSE:HUM) Stock Position Trimmed by Metis Global Partners LLC

Metis Global Partners LLC decreased its position in Humana Inc. (NYSE:HUM) by 0.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 5,002 shares of the insurance provider’s stock after selling 43 shares during the period. Metis Global Partners LLC’s holdings in Humana were worth $1,584,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in HUM. Swedbank AB increased its position in Humana by 3.0% in the 3rd quarter. Swedbank AB now owns 105,976 shares of the insurance provider’s stock valued at $33,567,000 after acquiring an additional 3,085 shares during the period. Heritage Oak Wealth Advisors LLC acquired a new position in shares of Humana during the second quarter valued at $3,456,000. Mandatum Life Insurance Co Ltd lifted its holdings in Humana by 115.4% in the third quarter. Mandatum Life Insurance Co Ltd now owns 14,000 shares of the insurance provider’s stock worth $4,434,000 after purchasing an additional 7,500 shares during the period. APG Asset Management US Inc. grew its position in Humana by 3.0% in the 2nd quarter. APG Asset Management US Inc. now owns 67,669 shares of the insurance provider’s stock valued at $25,274,000 after buying an additional 1,955 shares in the last quarter. Finally, Cetera Advisors LLC increased its stake in Humana by 472.1% during the 1st quarter. Cetera Advisors LLC now owns 10,098 shares of the insurance provider’s stock valued at $3,501,000 after buying an additional 8,333 shares during the period. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Stock Performance

Shares of HUM stock opened at $275.67 on Friday. The stock’s fifty day simple moving average is $281.36 and its 200-day simple moving average is $331.61. The company has a market capitalization of $33.19 billion, a price-to-earnings ratio of 24.42, a P/E/G ratio of 2.29 and a beta of 0.52. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67. Humana Inc. has a 1-year low of $213.31 and a 1-year high of $527.18.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, beating analysts’ consensus estimates of $3.48 by $0.68. The company had revenue of $29.30 billion for the quarter, compared to the consensus estimate of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%. On average, sell-side analysts predict that Humana Inc. will post 15.83 earnings per share for the current fiscal year.

Humana Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be paid a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.28%. The ex-dividend date of this dividend is Tuesday, December 31st. Humana’s dividend payout ratio (DPR) is currently 31.36%.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. KeyCorp assumed coverage on shares of Humana in a research note on Friday, October 11th. They issued a “sector weight” rating for the company. TD Cowen increased their price target on Humana from $261.00 to $268.00 and gave the company a “hold” rating in a research note on Monday, November 4th. Deutsche Bank Aktiengesellschaft dropped their price objective on Humana from $349.00 to $250.00 and set a “hold” rating on the stock in a research note on Thursday, October 3rd. Barclays raised their target price on Humana from $250.00 to $253.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Finally, Wells Fargo & Company dropped their price target on shares of Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Twenty equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, Humana has a consensus rating of “Hold” and a consensus price target of $315.86.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.